Long Term Therapy with Nebivolol in Patients with Hypertension

Abstract

SummaryNebivolol, a {iI-selective {i-blocker, was studied over a period of 6 months in patients with hypertension. The purpose of the study was to determine the efficacy, dose range and tolerability of the drug.42 patients with hypertension were recruited into the study. After a 4-week placebo run-in, patients received nebivolol 5, 7.5 or IOmg sequentially until normalisation of blood pressure was achieved. Blood pressure was measured (using a Hawksley random-zero sphygmomanometer) after 5 minutes in the supine position, and sitting.Diastolic blood pressure normalised (.:;: 95mm Hg; p = < 0.01) in 37 patients (88%) on nebivolol 5mg. The 5 remaining patients did not respond to 5, 7.5 or 10mg doses.Adverse effects occurred in 10 patients (23.8%) during the placebo run-in and in 7 patients (16.6%) during nebivolol treatment (p = NS).Nebivolol was a safe and efficacious drug at the 5mg dose.